Neurol. praxi. 2011;12(4):270-275
Most common pittfalls and mistakes in the diagnosis and management of Parkinson’s disease
- I. neurologická klinika LF MU a FN u sv. Anny, Brno
Although Parkinson´s disease is neurodegenerative disorder where causal treatment is still non-existing, there is always necessity
to make correct diagnosis, to differentiate secondary parkinsonian syndromes or other entities mimicking or presenting with
parkinsonian syndrome. The introduction of correct treatment in correct time is the key. The absence of systematic history taking,
complete neuro-exam with corresponding laboratory and other examinations, the delay of the introduction of symptomatic drugs,
the continuation of obsolete treatment, inadequadate dose of dopaminergic drugs, confusion of side-effects for inefficacy and lack
of time for our patients are most commonly seen pittfalls and mistakes.
Keywords: Parkinson´s disease, non-motor complications, motor complications, diagnosis, treatment
Published: July 29, 2011 Show citation
References
- Brooks DJ. Imaging dopamine transporters in Parkinson's disease. Biomark Med 2010; 4(5): 651-660.
Go to original source... 
Go to PubMed... - Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-379. Go to original source... Go to PubMed...
- Gaenslen A, Berg D. Early diagnosis of Parkinson's disease. Int Rev Neurobiol 2010; 90: 81-92. Go to original source... Go to PubMed...
- Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010; 68(2): 201-206. Go to original source... Go to PubMed...
- Hornykiewicz O, Kisk SJ. Biochemical pathophysiology of Parkinson´s disease. Adv Neurol 1986; 45: 19-34.
- Kaňovský P, Bareš M, Dufek J, Varga M, Rektor I. Senzitivita a specificita zátěžové polymyografie v diferenciální diagnostice tremoru horních končetin. Ces Slov Neurol Neurochir 2002; 65/98(5): 340-346.
- Kaňovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of two year, prospective follow-up. Mov Disord 2002; 17(1): 188-191. Go to original source... Go to PubMed...
- Kaňovský P, Kubová D, Bareš M, Hortová H, Streitová H, Znojil V, Rektor I. Suppression of L-DOPA induced dyskinesias in advanced Parkinsons disease by continuous subcutaneous infusions of apomorphine- Results of one year, prospective follow-up. Ces Slov Neurol Neurochir 2002; 65/98(1): 9-14. Go to original source...
- Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, Sterlacci W, Maeir H, Poewe W, Lees AJ. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov Disord 2010; 25(15): 2508-2515. Go to original source... Go to PubMed...
- Minen MT, Louis ED. Emergence of Parkinson's disease in essential tremor: a study of the clinical correlates in 53 patients. Mov Disord 2008; 23(11): 1602-1605. Go to original source... Go to PubMed...
- Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66(7): 996-1002. Go to original source... Go to PubMed...
- Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal LDOPA infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223. Go to original source... Go to PubMed...
- Okun MS, Foote KD. Parkinson's disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Rev Neurother 2010; 10(12): 1847-1857. Go to original source... Go to PubMed...
- Reichmann H. Clinical criteria for the diagnosis of Parkinson's disease. Neurodeg Dis 2010; 7(5): 284-290. Go to original source... Go to PubMed...
- Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E. End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment. Clin Neuropharmacol 2006; 29(6): 312-321. Go to original source... Go to PubMed...
- Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 11; 66(7): 968-975. Go to original source... Go to PubMed...
- Valls-Solé J. Neurophysiological characterization of parkinsonian syndromes. Neurophysiol Clin 2000; 30(6): 352-367. Go to original source... Go to PubMed...
- Weintraub D, Comella CL, Horn S. Parkinson's disease-Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 2008; 14(Suppl 2): S40-48. Review.
- Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005; 13(10): 844-851. Review. Go to original source... Go to PubMed...